Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Michael Andreeff

Showing results (351-360 of 504) with videos related to

Pageof 51
Sort By:
Blood|June 24, 2016
DOT1L as a therapeutic target for the treatment of DNMT3A-mutant acute myeloid leukemiaRachel E Rau, Benjamin A Rodriguez, Min Luo, et al.
Cancer|September 23, 2016
Persistence of minimal residual disease assessed by multiparameter flow cytometry is highly prognostic in younger patients with acute myeloid leukemiaFarhad Ravandi, Jeffrey Jorgensen, Gautam Borthakur, et al.
Haematologica|June 10, 2017
Combined targeting of STAT3 and STAT5: a novel approach to overcome drug resistance in chronic myeloid leukemiaKaroline V Gleixner, Mathias Schneeweiss, Gregor Eisenwort, et al.
Blood|July 22, 2021
Venetoclax enhances T cell-mediated antileukemic activity by increasing ROS productionJong Bok Lee, Dilshad H Khan, Rose Hurren, et al.
Blood|October 11, 2003
Treatment of Philadelphia chromosome-positive acute lymphocytic leukemia with hyper-CVAD and imatinib mesylateDeborah A Thomas, Stefan Faderl, Jorge Cortes, et al.
Cancer Biology & Therapy|July 13, 2012
Regulation of HIF-1α signaling and chemoresistance in acute lymphocytic leukemia under hypoxic conditions of the bone marrow microenvironmentOlga Frolova, Ismael Samudio, Juliana Maria Benito, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|February 22, 2018
Disruption of Wnt/β-Catenin Exerts Antileukemia Activity and Synergizes with FLT3 Inhibition in <i>FLT3</i>-Mutant Acute Myeloid LeukemiaXuejie Jiang, Po Yee Mak, Hong Mu, et al.
Cytometry. Part a : the Journal of the International Society for Analytical Cytology|January 20, 2015
Single-cell mass cytometry reveals intracellular survival/proliferative signaling in FLT3-ITD-mutated AML stem/progenitor cellsLina Han, Peng Qiu, Zhihong Zeng, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|December 18, 2008
A phase I study of the pan bcl-2 family inhibitor obatoclax mesylate in patients with advanced hematologic malignanciesAaron D Schimmer, Susan O'Brien, Hagop Kantarjian, et al.
Leukemia & Lymphoma|August 7, 2020
Survivorship in AML - a landmark analysis on the outcomes of acute myelogenous leukemia patients after maintaining complete remission for at least 3 yearsCatherine Kendall Major, Hagop Kantarjian, Koji Sasaki, et al.
Pageof 51

Showing results (351-360 of 504) with videos related to

Sort By:
Pageof 51
Blood|June 24, 2016
DOT1L as a therapeutic target for the treatment of DNMT3A-mutant acute myeloid leukemiaRachel E Rau, Benjamin A Rodriguez, Min Luo, et al.
Cancer|September 23, 2016
Persistence of minimal residual disease assessed by multiparameter flow cytometry is highly prognostic in younger patients with acute myeloid leukemiaFarhad Ravandi, Jeffrey Jorgensen, Gautam Borthakur, et al.
Haematologica|June 10, 2017
Combined targeting of STAT3 and STAT5: a novel approach to overcome drug resistance in chronic myeloid leukemiaKaroline V Gleixner, Mathias Schneeweiss, Gregor Eisenwort, et al.
Blood|July 22, 2021
Venetoclax enhances T cell-mediated antileukemic activity by increasing ROS productionJong Bok Lee, Dilshad H Khan, Rose Hurren, et al.
Blood|October 11, 2003
Treatment of Philadelphia chromosome-positive acute lymphocytic leukemia with hyper-CVAD and imatinib mesylateDeborah A Thomas, Stefan Faderl, Jorge Cortes, et al.
Cancer Biology & Therapy|July 13, 2012
Regulation of HIF-1α signaling and chemoresistance in acute lymphocytic leukemia under hypoxic conditions of the bone marrow microenvironmentOlga Frolova, Ismael Samudio, Juliana Maria Benito, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|February 22, 2018
Disruption of Wnt/β-Catenin Exerts Antileukemia Activity and Synergizes with FLT3 Inhibition in <i>FLT3</i>-Mutant Acute Myeloid LeukemiaXuejie Jiang, Po Yee Mak, Hong Mu, et al.
Cytometry. Part a : the Journal of the International Society for Analytical Cytology|January 20, 2015
Single-cell mass cytometry reveals intracellular survival/proliferative signaling in FLT3-ITD-mutated AML stem/progenitor cellsLina Han, Peng Qiu, Zhihong Zeng, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|December 18, 2008
A phase I study of the pan bcl-2 family inhibitor obatoclax mesylate in patients with advanced hematologic malignanciesAaron D Schimmer, Susan O'Brien, Hagop Kantarjian, et al.
Leukemia & Lymphoma|August 7, 2020
Survivorship in AML - a landmark analysis on the outcomes of acute myelogenous leukemia patients after maintaining complete remission for at least 3 yearsCatherine Kendall Major, Hagop Kantarjian, Koji Sasaki, et al.
Pageof 51